First Tracks Biotherapeutics enters the second week of July with an interesting split: the Street is firmly in the bull camp, yet the stock has given back ground after a strong month, and institutional ownership tells a complicated story of a major holder who already cashed out.
The Street's positioning on TRAX is broadly constructive, but the analyst picture is fresher than most clinical-stage biotechs enjoy. Every coverage initiation since late April has carried a bullish rating — JP Morgan, Barclays, Wells Fargo, Piper Sandler, UBS, and Leerink all came in with Overweight, Outperform, or Buy ratings in a concentrated wave following what appears to have been a significant corporate event. Today, HC Wainwright reiterated its Buy rating and $30 target, holding steady after the stock's recent drift. Price targets across the group range widely — from $30 at the lower end to $54 from Piper Sandler — with a consensus mean of $38.13 against a current price of $19.78, implying the Street collectively sees roughly 93% upside from here. That said, the absence of any target increase or upgrade in this reiteration suggests conviction is stable rather than building.
The bull and bear cases mirror each other neatly. Bulls point to rosnilimab's completed Phase 2b data in rheumatoid arthritis as the clearest evidence that the ANB033 and ANB101 pipeline has real clinical legs. Bears counter that the company remains pre-revenue, depends on external manufacturing, and faces a crowded autoimmune space where a 2029 commercial launch at $55,000 per treatment could struggle to differentiate. That framing — genuine optionality against a long runway to revenue — is the central tension driving the divergent price targets.
Lending conditions offer no particular insight into short-side conviction. Availability is extremely loose at 473%, meaning there are roughly five shares available to borrow for every one already lent out — well above the 52-week low of 52.7%. Cost to borrow is negligible at 0.55%, barely changed on the week, and the borrow market has been consistently relaxed for months. Short interest itself has fallen around 30% over the past month, from roughly 4.9 million shares in late May to 3.2 million now, suggesting shorts have been covering into the stock's 19% monthly price gain rather than pressing new positions. Options positioning reinforces this non-confrontational tone: the put/call ratio of 0.23 sits slightly below its 20-day average, meaning call activity continues to dominate — consistent with the broader bullish analyst tilt, not hedging behaviour.
The institutional holder table raises one flag worth noting. EcoR1 Capital entered as a 9.1% owner when it disclosed a stake in late April. But the insider table shows EcoR1 sold approximately $65 million worth of shares on April 20 — before that disclosure date, suggesting this reflects a post-transaction residual position rather than a fresh accumulation. That transaction, at $13.81 per share, was executed well below the current $19.78 price, and EcoR1 retains just over 3.1 million shares. The passive giants — BlackRock, State Street, and Vanguard — have all reported fresh positions as of June 30, consistent with index inclusion mechanics rather than active conviction.
Earnings are next due August 13. The two prior results where price-reaction data is available tell a mixed story: the May 14 print sent the stock down 8.3% on the day and nearly 9% over the following week, while the June 1 event produced a modest 1.1% gain before fading. With the stock up 19% over the past month heading into that print, the balance between clinical newsflow and quarterly financials — which will show only pipeline spend, not revenue — is the dynamic worth tracking most closely.
See the live data behind this article on ORTEX.
Open TRAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
